United Therapeutics Corporation Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
United Therapeutics Corporation (UTHR) holds an ST Score of 56.6 out of 100 (B-), with its strongest factor being Profitability (A+) and its weakest Valuation (D-). Analysts rate UTHR Buy across 30 ratings with a $650.00 average price target (+0.3% vs the current $494.63).
- Strongest
- ProfitabilityA+
- Weakest
- ValuationD-
All factor grades
- ProfitabilityA+
- ForecastB+
- Financial StrengthB
- MomentumB-
- GrowthC+
- SentimentC+
- ValuationD-
- Piotroski6/9
Contact
UTHR stock: frequently asked questions
What is UTHR's ST Score?
United Therapeutics Corporation (UTHR) has an ST Score of 56.6 out of 100, an overall grade of B-. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is UTHR a buy, sell, or hold?
Wall Street's consensus rating on UTHR is Buy based on 30 analyst ratings. Our own ST Score grades it B- (56.6/100). This is data, not investment advice — always do your own research.
What is UTHR's valuation grade?
United Therapeutics Corporation (UTHR) earns a valuation grade of D-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is UTHR's growth grade?
United Therapeutics Corporation (UTHR) earns a growth grade of C+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is UTHR's profitability grade?
United Therapeutics Corporation (UTHR) earns a profitability grade of A+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is UTHR's financial strength grade?
United Therapeutics Corporation (UTHR) earns a financial strength grade of B, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for UTHR?
The average analyst price target for United Therapeutics Corporation (UTHR) is $650.00 from 30 analysts, which is +0.3% versus the recent price of $494.63.
What is UTHR's Piotroski score?
United Therapeutics Corporation (UTHR) has a Piotroski F-Score of 6 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.